Tue, Sep 30, 2014, 7:43 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • racavalli racavalli Jan 29, 2013 3:13 PM Flag

    the article blasting AMPE is working well to help the shorts cover their position before major news hits

    Today's article is so obvious that it is an attempt to shake the tree hard so the shorts can gather al the stock they need to cover their short positions before a major announcement is released.

    If AMPE were vetted by major bankers and had a decent following, it would be at least a $20 stock today based on actual comps of what is out there now.

    Too bad though, it is not and we all have to sit tight and wait until the company makes an announcement. In the meanwhile, this article and the rest to surely follow will most likely drive the stock much much lower because it is way too easy to manipulate with articles by the shorts who are the only ones who are writing about the company that remains silent.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "If AMPE were vetted by major bankers and had a decent following"

      Why hasn't AMPE been vetted by major banks?

      "it is way too easy to manipulate with articles by the shorts who are the only ones who are writing about the company that remains silent."

      Interesting. I wonder if longs ever write articles to manipulate AMPE......

      • 2 Replies to ampiooooooh
      • This is a key question to the current valuation problem the company has had since day 1.

        When Ampio's shareholders and management decided to become a publicly traded company, they weighed their options. 1 - do traditional IPO and take a year longer and pay a million or more in the process......or.......buy a shelf company that is already approved for trading and is deemed to be liability free.

        To save time and money, they chose to buy a shelf company. That meant that no known bankers EVER had any knowledge of the company. No bankers ..... Except for the questionable and not followed Aegis and Fordham . . . . No coverage . . . . no visibility except for the visibility I brought to the company with my articles that were all true and where everything was substantiated.

        The basic simple fact that absolutely cannot be denied is that INVESTORS WILL NOT INVEST TO ANY SIGNIFICANT DEGREE IN ANY STOCK THAT IS NOT FOLLOWED BY MAJOR BANKERS. THAT IS A SIMPLE FACT. Look as hard as you can and you will never find any company whose stock did well for any extended period of time that was not covered by major or well known analysts and bankers.

        The only bankers the company has ever dealt with are tow very tiny, very unknown and very unfollowed firms called Fordham and Aegis.

        If you look into this, you will see that there is not one known banker who covers AMPE.

        Management says they don't want to pay the high fees.

        I undertand, but the big question is ...... was this wise?

        I personally do not think so because if they did the traditional IPO path, based on current comps in the marketplace, AMPE shares would be selling between $20 per share instead of $3.00 and headed lower for the short term.

        I have been accused of writing articles to pump the stock which implies there is going to be a dump and somebody will profit. First, there has never been a seller trying to take advantage of my articles and second, my ONLY mission was to share their unusually exciting story with the investment community that knows nothing about them and still doesn't because management doesn't have a clue about how their shares are valued and they certainly does not know how to get their story out. Everytime they issue a press release that is good news, the stock drops. What does that tell you.

        I believe this company knows what it is doing with their business and is going to surprise on the upside eventually even in spite of themselves, but I also believe their shares would be much much higher today , , , , and tomorrow, if they only knew how to get out of their own way and talk to shareholders the same way the more successful companies do.

        Sentiment: Strong Buy

      • let us not forget that the biggest moron Adam F likes to bash and help the shorts every now and then. It's a shame that he is a journalist and covers biotech/pharma.

    • Rich I know you support AMPE but can there be any truth in what the article says about the drugs being sort of worthless to some degree. They did explain why saying another company attempted to use the same drugs and failed ? And is there really going to be a company willing to invest in zertane and try to bring it to the market ? Or is that just wishful thinking ?. And what about AMPE the company doing all there trials outside the country ? I know its easy to blame the shorts for bringing it down but with no real proof the company has anything but good intentions re using old drugs in new ways ? sometimes just dosen`t cut it. I'm concerned about what hes says about maybe the next thing we see will be inside dumping Man that alone at this point would bring the company to there knees Rich I think the CEO gotta step up and take a stand and not you , if he wants people to believe in his company not to mention share holders are losing there shirts waiting for what your saying good news ? Is it really coming or Are you on the other side of the shorts helping the company fool the stock holders . Because Rich action speaks louder then words and good intentions. DON'T KNOW WHO TO BELIEVE AT THIS POINT and so do many others Whats going on here where is the good news you been raving about and when is it coming ? Thanks I'm sure I speak for many frustrated share holders who are losing there savings as we speak ?????

      • 1 Reply to goingreen11
      • Goinggreen11

        First of all, I love your handle goinggreen.

        I have done more due diligence on this company then even the analyst at Aegis whose report had a few major flaws and was far too conservative. I spoke with him at length and he admitted that he was forced to be ultra conservative by his company.

        As far as the value of the drugs . . . Zertane already passed a large phase II trial in Europe. Biovale did give up on the trial but there was a different reason than what we hear the bears say. The real reason is that BV was under a corporate wide mandate to abandon ALL R&D trials that were not pivotal and Zertane was one at the time. When they abandoned it and it reverted back to AMPE, BV did not even look at the trial data. If they did, they would have fought to keep it. The trial results were a smashing success. Please allow me to attempt to translate Macaluso's presentation from last week. AMPE already completed that portion leading to the current pivotal phase III trial in the U.S. that has to do with creating the questionnaire for the patients in the trial. The questionnaire must be accepted by the FDA before the company can execute the final trial. The company has a major pharma partner ready to announce a deal as soon as the FDA announces formal acceptance of the questionnaire. They might accept it or they might reject it. My guess is that since the FDA already provided guidance for this pivotal trial, the company probably had a pretty good idea as to how to word the questionnaire. Therefore, it seems more probable that the FDA will soon announce acceptance that will clear the way for the company to make a major announcement that will likely send shares soaring. In fact, I believe very strongly that the new SA article blasting AMPE was put out by the shorts so they can cover their short position at low prices before the stock rockets and kills them. Anything can happen, but that is my take.

        Then there is Ampion . . . and Optina . . . and NCE001 . . . and ORP . . . and 150 more compounds that they own. I have personally interviewed the senior director who ran the phase II trial in Australia and if you heard the results you would be buying all the shares at any price. I predict that Ampion is going to become the new standard in the Anti Inflammatory market and become a mega blockbuster.

        Optina is going to destroy Lucentis and Eyelea. In fact, REGN is going to get hammered when Optina gets approved. When you read the prior results and when you understand the mechanism of how it works, it is light years better than anything in the market.

        Management is not going to sell their shares at these ridiculously low prices unless one of them goes personally bankrupt and needs money.

        Putting Zertane aside until we hear from the FDA on the questionnaire, Ampio and Optina are both ready to start trials that are only 12 weeks. That's fast. Look at any stock 12 months prior to FDa approval and you'll see an explosion. AMPE is just about at that point.

        NCE001 is getting accelerated and it is an entirely new class of cancer treatment that is going to make big headlines in the next year. This one will be bigger than Texas.

        And ORP is about to surprise very big.

        Love what the shorts do to provide more liquidity but you have to be a mental case to be short this $4 stock. When it happens it will be instantaneously fast with no warning and it is going to be extremely painful to the shorts.

        I know it seems like a long time but in my opinion if you can just stop listening to all the noisey chatter from traders who NEVER make a dime for very long, you will be rewarded HUGELY. It's only the holders who wind up making the big money. The traders have a lot of fun but at the expense of big and sustained profits. Never met one who lasted more than a few years unless they keep burning other peoples money.

        Just my opinion and i know this company FAR better than anyone outside of the company and they don't know how to talk to investors and they certainly don't know how to tell their story because if they did, their stock would be miles higher today and not under pressure from some small time short sleezebags who take candy from babies.

        Maybe they will get back on track of getting their real story out to investors who would love to know the truth.

        Good luck going goinggreen11

        Sentiment: Strong Buy

3.53-0.19(-5.11%)Sep 30 4:04 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.